Steven Cohen’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.9M Sell
1,625,019
-762,007
-32% -$14M 0.03% 794
2026
Q2
$44.1M Buy
2,387,026
+1,470,884
+161% +$23.3M 0.05% 478
2026
Q1
$13.7M Buy
916,142
+288,640
+46% +$4.51M 0.02% 1032
2025
Q4
$11.4M Sell
627,502
-426,481
-40% -$7.2M 0.01% 1278
2025
Q3
$13.4M Buy
+1,053,983
New +$9.06M 0.02% 689
2023
Q2
– Sell
-4,586
Closed -$1.93M – 2171
2023
Q1
$1.93M Buy
4,586
+2,500
+120% +$1.97M 0.01% 986
2022
Q4
$2.52M Hold
2,086
– – 0.01% 894
2022
Q3
$1.66M Hold
2,086
– – 0.01% 962
2022
Q2
$3M Hold
2,086
– – 0.01% 838
2022
Q1
$4.36M Hold
2,086
– – 0.02% 738
2021
Q4
$10.2M Hold
2,086
– – 0.04% 505
2021
Q3
$13.1M Buy
2,086
+1,633
+360% +$13.2M 0.06% 424
2021
Q2
$4.27M Sell
453
-398
-47% -$3.33M 0.02% 631
2021
Q1
$7.4M Buy
+851
New +$8.04M 0.03% 497

Other funds holding AVTX

Steven Cohen's AVTX Position: Q3 2026 in Review

Steven Cohen reduced its Avalo Therapeutics (AVTX) stake by 32% in Q3 2026, selling an estimated $14M and leaving 1,625,019 shares worth $24.9M. The position accounts for 0.03% of the portfolio, ranked #794.

Steven Cohen first reported a position in AVTX in Q1 2021 and has held it in 14 quarters since. The position peaked at $44.1M in Q2 2026. 145 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Steven Cohen held 1,625,019 shares of Avalo Therapeutics worth $24.9M as of Q3 2026.
  • Steven Cohen sold 762,007 Avalo Therapeutics shares in Q3 2026, an estimated $14M.
  • Avalo Therapeutics made up 0.03% of Steven Cohen's portfolio in Q3 2026, its #794 holding.
  • Steven Cohen first reported a position in Avalo Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • Steven Cohen's Avalo Therapeutics position peaked at $44.1M in Q2 2026.
  • 145 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.